<DOC>
	<DOCNO>NCT02973503</DOCNO>
	<brief_summary>A Phase 3 , Global , Multicenter , Open-Label Study Investigate Efficacy Elbasvir/Grazoprevir Fixed-Dose Combination 8 Weeks Treatment-Naïve , HCV GT1b-Infected Patients , non-severe fibrosis The primary objective study follow : - To evaluate efficacy Elbasvir/Grazoprevir Fixed-Dose Combination 8 Weeks Treatment-Naïve , HCV GT1b-Infected Patients , non- severe fibrosis measure proportion subject sustain viral response 12 week cessation treatment ( SVR 12 ) . - To evaluate safety tolerability EBV/GZR treatment The secondary objective study follow : - To determine proportion subject attain SVR 4 24 week cessation treatment ( SVR4 SVR24 ) - To evaluate proportion subject virologic failure - To evaluate kinetics circulate HCV RNA treatment cessation treatment . - To evaluate emergence viral resistance EBV/GZR treatment cessation treatment</brief_summary>
	<brief_title>Study Investigate Efficacy Elbasvir/Grazoprevir Fixed-Dose Combination 8 Weeks Treatment-Naïve , HCV GT1b-Infected Patients , With Non-severe Fibrosis</brief_title>
	<detailed_description>Seventy treatment-naïve subject chronic HCV GT1b infection without cirrhosis enrol . There one treatment group EBV/GZR ( 50/100 mg ) daily without regard food 8 week . EBV/GZR manufacture 50/100 mg tablet oral administration . Subjects take 1 tablet daily without regard food . Screening assessment complete within 28 day Day 1 visit . The screening window extend 42 day subject require liver biopsy , extenuate circumstance . All subject complete follow study visit : Screening , Day 1 , on-treatment visit end week 2 , week 4 week 8 . Posttreatment visit occur Weeks 4 , 12 , 24 last dose study drug . All subject complete posttreatment Week 4 12 visit . Subjects achieve SVR12 ( HCV RNA &lt; LLOQ posttreatment Week12 ) complete posttreatment Week 24 visit . Screening assessment include physical examination , medical history , height , weight , vital sign , adverse event related screening procedure , concomitant medication , safety laboratory test ( include hematology , chemistry , coagulation ) , HCV RNA , serology ( HCV , HBV ) , serology and/or antigen test HIV , HCV genotyping , hemoglobin A1c ( HbA1c ) , assessment absence cirrhosis severe fibrosis ( include Fibrotest® Fibroscan® ) , serum β-human chorionic gonadotropin ( β-hCG ) ( females child-bearing potential ) , urinalysis . On-treatment assessment include adverse event ( AEs ) , concomitant medication , study medication dispensation pill count , physical examination , weight , vital sign , safety laboratory test , HCV RNA , urine pregnancy test ( female child bear potential ) . Posttreatment assessment include Aes , concomitant medication , vital sign , safety laboratory test ( include hematology , chemistry , coagulation ) , HCV RNA , urine pregnancy test ( female child-bearing potential ) .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<criteria>Willing able provide write informed consent Male female , age ≥ 18 year Body Mass Index ( BMI ) ≥ 18 kg/m2 HCV RNA ≥ 104 IU/mL Screening Chronic HCV infection ( ≥ 6 month ) document prior medical history liver biopsy , genotype 1b virus . ( Positive anti HCV antibody , HCV RNA , HCV genotype ) Treatmentnaïve prior exposure IFN , RBV , approve experimental HCVspecific DAA Non severe fibrosis ( F &lt; 2 ) accord Metavir score biopsy perform elasticity measure Fibroscan® low 9.5 kPa Fibrotest® low 0.59 Fibrometer® low 0.63 Fibroscan® perform . Females childbearing potential ( define protocol Appendix 4 ) must negative serum pregnancy test screen negative urine pregnancy test Day 1 prior enrollment Male subject female subject childbearing potential engage heterosexual intercourse must agree use 2 effective method ( ) contraception least two week prior Day 1 14 day last dose study drug . If acceptable local regulatory agency , method birth control allow study : intrauterine device ( IUD ) , diaphragm spermicide , hormonal contraceptive ( e.g. , birth control pill , transdermal patch , injectables ) , contraceptive sponge , female condom , male condom spermicide vasectomy . Note : Periodic abstinence ( e.g. , abstinence certain calendar day , abstinence ovulation period , use symptothermal method , use postovulation method withdrawal ) acceptable method contraception . A female subject reproductive potential eligible without require use contraception . A female subject reproductive potential define one either 1 ) reach natural menopause ( defined 12 month menses without alternative medical cause ) , 2 ) 6 week post surgical bilateral oophorectomy without hysterectomy , 3 ) bilateral tubal ligation . A male subject reproductive potential eligible without require use contraception . A male subject reproductive potential define : one undergone successful vasectomy . A successful vasectomy define : ( 1 ) microscopic documentation azoospermia , ( 2 ) vasectomy 2 year ago resultant pregnancy despite sexual activity post vasectomy . Lactating female must agree discontinue nurse start study drug Subject must generally good health , exception chronic HCV infection , determine Investigator Subject must able comply dose instruction study drug administration able complete study schedule assessment Is age legal consent , mentally legally incapacitate , significant emotional problem time prestudy screen visit expect conduct study history clinically significant psychiatric disorder , opinion investigator , would interfere study procedure . Current prior history follow : Clinically significant illness ( HCV ) major medical disorder may interfere subject treatment , assessment compliance protocol ; subject currently evaluation potentially clinically significant illness ( HCV ) also exclude Gastrointestinal disorder postoperative condition could interfere absorption study drug Difficulty blood collection and/or poor venous access purpose phlebotomy History decompensation ( e.g. , clinical ascites , encephalopathy , and/or variceal hemorrhage ) Solid organ transplantation ( include hematopoietic stem cell transplant ) kidney , cornea hair . Significant cardiac disease Unstable psychiatric condition include hospitalization , suicidal attempt , and/or period disability result psychiatric illness within 2 year prior Screening Malignancy within 5 year prior Screening , exception specific cancer cure surgical resection ( e.g. , basal cell skin cancer , etc. ) . Subjects evaluation possible malignancy eligible Significant drug allergy ( e.g. , hepatotoxicity ) Subject follow laboratory parameter Screening : ALT &gt; 10 x upper limit normal ( ULN ) AST &gt; 10 x ULN Direct bilirubin &gt; 1.5 x ULN Platelets &lt; 75,000/μL HbA1c &gt; 8.5 % Creatinine clearance &lt; 50 mL/min calculate CockcroftGault equation Hemoglobin &lt; 10 g/dL Albumin &lt; 3 g/dL INR &gt; 1.5 x ULN unless subject know hemophilia stable anticoagulant regime affect INR Chronic liver disease nonHCV etiology ( e.g. , hemochromatosis , Wilson 's disease , alfa1 antitrypsin deficiency , cholangitis ) Infection hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV ) Clinicallyrelevant alcohol drug abuse within 12 month Screening . Alcohol , intravenous drug , inhalational ( include marijuana ) , psychotropic , narcotic , cocaine use , prescription overthecounter drug : within 1 year screen visit , short , judge investigator capable comply study procedure receive opiate agonist substitution therapy within 1 year screen visit , short , judge investigator capable comply study procedure history marijuana use deem excessive physician investigator interfere subject 's daily function . If subject 's marijuana use deem excessive interfere daily function , subject must agree discontinue current use recreational marijuana prior entry trial throughout trial period A positive drug screen exclude subject unless explain prescribed medication ; diagnosis prescription must approve investigator Use prohibit concomitant medication list Section 5.5 protocol within 2 week prior day 1 . Known hypersensitivity study drug , metabolite , formulation excipient currently participate participate study investigational compound within 30 day sign informed consent willing refrain participate another study . Collection additional blood , urine , tissue sample additional data , beyond specify protocol , prohibit ( related subject 's medical care ) . ( female ) pregnant , lactating , expect conceive donate egg , childbearing potential unwilling commit two method birth control throughout treatment completion treatment ( see Inclusion Criteria ) ; male subject plan impregnate provide sperm donation female sexual partner childbearing potential unwilling commit use two method birth control throughout treatment completion treatment ( see Inclusion Criteria ) . lifethreatening SAE screen period . 2. member family member investigational study staff sponsor staff directly involve study . evidence history chronic hepatitis cause HCV , include limited nonalcoholic steatohepatitis ( NASH ) , druginduced hepatitis , autoimmune hepatitis . NOTE : Subjects history acute nonHCVrelated hepatitis , resolve &gt; 6 month study entry , may enrol . For subject diagnose diabetes mellitus , document HbA1c &gt; 8.5 % ( exclude uncontrolled diabetes ) . Has follow condition : . Subject history gastric surgery ( e.g. , staple , bypass ) subject history malabsorption disorder ( e.g. , celiac sprue disease ) . Any medical condition requiring , likely require , chronic systemic administration corticosteroid course trial . Has exclusionary laboratory value list ( see Table 5 unit conversion laboratory value specify ) : Note : If laboratory exclusion criterion meet , site may abnormal value retested one time . Table 5 : Exclusionary laboratory value : Laboratory Assessment hemoglobin &lt; LLN ( low limit normal ) labora=tory reference range neutrophil &lt; 1.5 x 103/μL ( &lt; 1.2 x 103/μL Blacks ) platelets &lt; 75 x 103/μL direct bilirubin &gt; 1.5 x ULN Total Bilirubin &gt; 1.6 mg/dL unless history Gilbert 's disease . ( If Gilbert 's disease propose etiology , must document subject 's chart ) Serum Albumin &lt; 3.0 g/dL ( low limit normal ) laboratory reference range creatinine clearance &lt; 50 mL/min INR &gt; 1.5 ALT &gt; 350 AST &gt; 350</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Genotype 1B</keyword>
	<keyword>Non Severe Fibrosis</keyword>
	<keyword>Treatment Naïve</keyword>
	<keyword>8 Weeks Treatment</keyword>
	<keyword>Elbasvir/Grazoprevir Combination</keyword>
</DOC>